France – World

Daily ⁣Steps Linked to Considerably Delayed Cognitive Decline in Alzheimer’s risk Group

New research published in Nature Medicine suggests a simple‍ increase in daily walking can dramatically slow ‍the progression of ⁤cognitive decline, even in individuals with early Alzheimer’s ‍indicators.

A study conducted by American researchers analyzed data from 296 participants ‌aged 50 to 90, all initially cognitively healthy. Researchers utilized pedometers to track physical activity levels and monitored participants ⁣for two to fourteen years, conducting annual cognitive assessments. Brain scans were used to ‌measure levels of beta-amyloid⁢ plaques ‍and tau proteins – key biomarkers associated with Alzheimer’s disease.

The findings reveal a strong correlation between step ⁣count and cognitive health. Individuals walking between 3,000 and 5,000⁤ steps daily – roughly 2 to 4 kilometers – experienced, on average, a three-year delay in cognitive ⁢decline. Remarkably, those increasing thier daily steps to between 5,000‌ and 7,500⁢ saw their cognitive decline postponed by a ample seven years.

Specifically, the study demonstrated that in individuals with ⁢high levels ⁢of beta-amyloid, increasing‌ daily step count was directly linked to slower cognitive decline and ​ a slower accumulation of ‍tau proteins. Conversely, a sedentary ​lifestyle was associated with a more rapid buildup of tau and a faster rate‌ of cognitive ⁢deterioration.

“These findings explain ⁤why some peopel⁣ who show signs of Alzheimer’s disease do not decline as quickly as others,” explained Dr. Jasmeer Chhatwal,⁤ lead author‍ of the study. ⁤”Lifestyle‍ factors appear to influence the early stages of the disease, suggesting that lifestyle‍ changes can slow the onset ⁢of cognitive symptoms ⁣if⁣ we act early.”

The research underscores​ the⁢ importance of even modest increases in physical activity. ⁤Dr. Chhatwal emphasizes that “every step counts,” and a goal of 3,000 daily steps is a readily achievable​ target, even for older adults or those not‍ regularly engaged in ⁤exercise. This​ offers a potentially accessible and impactful strategy for mitigating the ‍effects of ​Alzheimer’s⁢ disease.

COVID-19 Vaccines Show‍ Promise in Boosting Cancer Immunotherapy

Unexpectedly,⁢ COVID-19 mRNA vaccines are demonstrating a potential benefit for⁣ cancer ‌patients undergoing ⁢immunotherapy.​ Research suggests that⁢ receiving ⁢a COVID-19 vaccine within 100 days of starting immunotherapy treatment is linked to improved survival rates in patients with advanced⁤ skin (melanoma) or lung cancer.

Patients treated with immune checkpoint⁤ inhibitors – therapies that block proteins ‍preventing the immune system from attacking cancer cells⁣ – were, on average, twice as likely to be ⁣alive three years after treatment if they had also received a COVID-19 vaccine.

A retrospective analysis of over​ 1,000 patients treated between 2019 and 2023 revealed ⁤significant differences in median survival. Patients ‍with advanced non-small cell lung ‍cancer who were vaccinated had⁣ a median survival of 37.33‍ months, compared to 20.6 ​months for ​unvaccinated patients. for metastatic melanoma, vaccinated patients showed a ⁣promising trend with⁤ survival ‌not yet reached, while unvaccinated‍ patients had a ‌median survival of 26.67‍ months (with over half of the vaccinated group still alive).

Researchers believe the mRNA ⁢vaccines ​”train” the immune system to recognize and eliminate cancer cells. ‌Dr. Adam Grippin, lead author of the study, explains that combining these vaccines with immune ⁣checkpoint⁢ inhibitors ⁣creates a powerful anti-tumor immune response, leading to dramatic improvements in survival.Previous ⁢research had indicated mRNA vaccines are potent immune ‍activators, even without directly targeting tumors.

Studies ‌show the vaccines act ‍as an “alarm,” putting the ​immune ⁣system on high alert. Cancer ⁤cells produce a ⁤protein, PD-L1, which can suppress the immune response, ​but checkpoint inhibitors block this protein, allowing⁣ the activated immune system to attack. this ‌mechanism was also ⁣observed in clinical studies, with increased immune activation and PD-L1 expression on tumors in vaccinated⁢ individuals.

Notably, patients who initially responded ⁤poorly to‍ immunotherapy experienced the most significant benefit from the vaccine-immunotherapy⁣ combination – their survival rate was ⁣nearly five times⁤ higher ⁤than those who remained unvaccinated.

These findings, presented⁢ at the European Society for ⁤Medical Oncology (ESMO) congress and published in ⁣ Nature, are currently being ‍validated‌ in a randomized Phase III clinical ‍trial. If confirmed, ⁢the results⁣ coudl lead to ​the inclusion⁤ of mRNA vaccines⁤ in standard cancer care‌ and perhaps pave the way for the development of even more effective, universal anti-cancer vaccines.